Androst Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 25-10-2024
- Paid Up Capital ₹ 5.00 M
as on 25-10-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 Cr
as on 25-10-2024
- Revenue %
(FY 2023)
- Profit -4222.03%
(FY 2023)
- Ebitda -1679.66%
(FY 2023)
- Net Worth -5.09%
(FY 2023)
- Total Assets -2.08%
(FY 2023)
About Androst Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹5.00 Cr.
Mitulkumar Zala and Pradip Darji serve as directors at the Company.
- CIN/LLPIN
U24246GJ2021PTC124216
- Company No.
124216
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Kheda, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Androst Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mitulkumar Zala  | Director | 19-Jul-2021 | Current |
| Pradip Darji | Director | 19-Jul-2021 | Current |
Financial Performance of Androst Biotech.
Androst Biotech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 4222.03% decrease in profit. The company's net worth dipped by a decrease of 5.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Androst Biotech?
Unlock access to Androst Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Androst Biotech India Private LimitedActive 2 years 5 months
Mitulkumar Zala and Pradip Darji are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 05 Mar 2024 | ₹5.00 Cr | Open |
How Many Employees Work at Androst Biotech?
Androst Biotech has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Androst Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Androst Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
